HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets

Review the latest evidence on the optimal use of HER2 HER3 and TROP2 antibody&ndash drug conjugates in breast gastrointestinal and lung cancers with an expert commentary plus a webcast with downloadable slides.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.